You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
PRODUCT
Vebreltinib Enteric Capsules(万比锐®)
It is the only MET inhibitor in China that has been approved for three indications (NSCLC and glioma)* and three indications have been included in China's National Reimbursement Drug List
[Indications]
-
NSCLC
Indication 1: Vebreltinib Enteric Capsule is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Indication 2: Vebreltinib Enteric Capsule is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) amplification.
-
Glioma
Indication 3: Adult patients with IDH mutant astrocytoma (WHO grade 4) with the PTPRZ1-MET fusion who have experienced treatment failure in prior therapies or glioblastoma with LGG history.
The latest revision date of the package insert for Vebreltinib Enteric Capsule is July 23, 2025.For any questions regarding the package insert, please contact the Quality Assurance Department via the following channels: Tel: 4006028668 (Weekdays 08:30 to 17:30) Email: chenduo@pearlbio.cn
*Till December of 2025
Andamertinib Benzoate Capsule (安比锐®)
Andamertinib – A New-Generation EGFR TKI Delivering Long-Lasting, Sustainable and Tolerable Treatment Solutions for NSCLC Patients with EGFR ex20ins
[Indications]
-
NSCLC
Indication : Andamertinib Benzoate Capsule is indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or following platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and who have been confirmed by testing to have an exon 20 insertion mutation in the epidermal growth factor receptor (EGFR).
For any questions regarding the latest revision of Andamertinib Benzoate Capsule, please contact the Quality Assurance Department via the following channels: Tel: 400-8878-788 (Weekdays 08:30 to 17:30) Email: wangjingang@avistonebio.com
*Till May of 2026
